S-5242-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Jim Banks (R-IN)
What it does
This bill would amend the Federal Food, Drug, and Cosmetic Act to let manufacturers of prescription drugs and biological products provide required prescribing information electronically instead of automatically including paper package inserts, as long as prescribers and dispensers can still request paper copies at no extra cost. It directs HHS to issue implementing regulations within one year and hold a public workshop within two years to further refine the format of this information.
Who benefits
Drug manufacturers and distributors, who would save printing, storage, and shipping costs on paper package inserts. Pharmacies and hospitals may benefit from easier access to searchable, up-to-date digital prescribing information. Health IT companies that build systems to deliver this information electronically may also see new business opportunities.
Who is hurt
Prescribers and dispensers without reliable internet or electronic systems, particularly in rural or under-resourced clinics, who may face friction requesting paper copies. Patients and providers who rely on immediate physical access to printed inserts during power or system outages. Smaller pharmacies or independent practices that may bear short-term administrative costs adjusting to new digital workflows before HHS regulations minimize such impacts.
Supporters argue
Supporters argue that paper package inserts are often outdated by the time they reach pharmacies, since drug labeling changes take months to filter into printed materials, while electronic formats can be updated instantly with the most current safety and dosage information. They contend this modernization reduces unnecessary manufacturing costs and environmental waste while preserving access, since the bill requires manufacturers to still provide paper copies on request at no additional cost.
Opponents argue
Opponents argue that shifting to electronic-only default access could disadvantage prescribers and dispensers in areas with unreliable internet access or older technology systems, potentially delaying access to critical safety information during emergencies. They contend that requiring a proactive request for paper copies places an extra burden on smaller or rural providers who may not know how to make such a request or may face delays before receiving it.
Constitutional context
This bill raises no significant constitutional questions; it operates within Congress's well-established Commerce Clause authority to regulate the interstate distribution and labeling of drugs, consistent with existing FDCA framework.
Checks and balances
Congress delegates rulemaking authority to HHS/FDA to implement the electronic labeling standard, with judicial review available post-Loper Bright if regulations exceed statutory text, and ordinary notice-and-comment rulemaking providing procedural checks.
Historical precedent
The FDA has previously allowed electronic distribution of certain prescribing information for pharmacies and hospitals (e.g., prescribing information via specific FDA guidance documents), though this bill would codify a broader statutory default in the FDCA itself.